Skip to main content
Log in

Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone

  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Purpose

To compare transarterial chemoembolization (TACE) monotherapy to combination TACE and microwave ablation (MWA) for local control of 3- to 5-cm hepatocellular carcinoma (HCC).

Methods

Patients with HCC between 3 and 5 cm treated with TACE monotherapy or combination TACE + MWA at a single institution between 2007 and 2016 were retrospectively reviewed. Twenty-four HCCs (median diameter 3.8 cm) in 16 patients (13 males; median age 64 years) were treated using TACE monotherapy. Combination TACE + MWA was used to treat 23 HCCs (median diameter 4.2 cm) in 22 patients (18 males; median age 61 years). Microwave ablation was performed at a target time of two weeks following TACE. Individual tumors were followed by serial contrast-enhanced CT or MR. Response to treatment was evaluated on a tumor-by-tumor basis using mRECIST criteria with the primary outcome being local tumor progression (LTP). Data were analyzed using Fisher’s exact test for categorical variables and Wilcoxon rank sum test for continuous variables. Time to LTP was estimated with the Kaplan–Meier method.

Results

Relative to TACE monotherapy, TACE + MWA provided a trend toward both a lower rate of LTP (34.8% vs. 62.5%, p = 0.11) and a higher complete response rate (65.2% vs. 37.5%; p = 0.12). Time to LTP (22.3 months vs. 4.2 months; p = 0.001) was significantly longer in the TACE + MWA group compared to TACE monotherapy.

Conclusions

Combination therapy with TACE and microwave ablation improves local control and increases time to LTP for 3–5 cm HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ferlay J, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013)

  2. Rahimi RS, Trotter JF (2015) Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence. Ann Gastroenterol 28(3):323–330

    PubMed  PubMed Central  Google Scholar 

  3. Maddala YK, Stadheim L, Andrews JC, et al. (2004) Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 10(3):449–455. https://doi.org/10.1002/lt.20099

    Article  PubMed  Google Scholar 

  4. Mazzaferro V, Battiston C, Perrone S, et al. (2004) Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 240(5):900–909. https://doi.org/10.1097/00054725-200411000-00024

    Article  PubMed  PubMed Central  Google Scholar 

  5. Millonig G, Graziadei IW, Freund MC, et al. (2007) Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 13(2):272–279. https://doi.org/10.1002/lt.21033

    Article  PubMed  Google Scholar 

  6. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022. https://doi.org/10.1002/hep.24199

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kothary N, Takehana C, Mueller K, et al. (2015) Watershed hepatocellular carcinomas: the risk of incomplete response following transhepatic arterial chemoembolization. J Vasc Interv Radiol 26(8):1122–1129. https://doi.org/10.1016/j.jvir.2015.04.030

    Article  PubMed  Google Scholar 

  8. Ni JY, Liu SS, Xu LF, Sun HL, Chen YT (2013) Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 19(24):3872–3882. https://doi.org/10.3748/wjg.v19.i24.3872

    Article  PubMed  PubMed Central  Google Scholar 

  9. Peng ZW, Zhang YJ, Chen MS, et al. (2013) Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 31(4):426–432. https://doi.org/10.1200/JCO.2012.42.9936

    Article  PubMed  Google Scholar 

  10. Brace CL (2009) Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences? Curr Probl Diagn Radiol 38(3):135–143. https://doi.org/10.1067/j.cpradiol.2007.10.001

    Article  PubMed  PubMed Central  Google Scholar 

  11. Yang WZ, Jiang N, Huang N, et al. (2009) Combined therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation for small hepatocellular carcinoma. World J Gastroenterol 15(6):748–752

    Article  PubMed  PubMed Central  Google Scholar 

  12. Seki T, Tamai T, Nakagawa T, et al. (2000) Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer 89(6):1245–1251. 10.1002/1097-0142(20000915)89:6<1245::aid-cncr8>3.0.co;2-f

    Article  PubMed  CAS  Google Scholar 

  13. Li W, Man W, Guo H, Yang P (2016) Clinical study of transcatheter arterial chemoembolization combined with microwave ablation in the treatment of advanced hepatocellular carcinoma. J Cancer Res Ther 12(Supplement):C217–C220. https://doi.org/10.4103/0973-1482.200598

    Article  PubMed  CAS  Google Scholar 

  14. Ginsburg M, Zivin SP, Wroblewski K, et al. (2015) Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation. J Vasc Interv Radiol 26(3):330–341. https://doi.org/10.1016/j.jvir.2014.10.047

    Article  PubMed  Google Scholar 

  15. Sacks D, McClenny TE, Cardella JF, Lewis CA (2003) Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol 14(9 Pt 2):S199–S202

    Article  PubMed  Google Scholar 

  16. Ahmed M (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update: supplement to the consensus document. J Vasc Interv Radiol 25(11):1706–1708. https://doi.org/10.1016/j.jvir.2014.09.005

    Article  PubMed  Google Scholar 

  17. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60

    Article  PubMed  CAS  Google Scholar 

  18. Chinn SB, Lee FT, Kennedy GD, et al. (2001) Effect of vascular occlusion on radiofrequency ablation of the liver. Am J Roentgenol 176(3):789–795. https://doi.org/10.2214/ajr.176.3.1760789

    Article  CAS  Google Scholar 

  19. Goldberg SN, Kamel IR, Kruskal JB, et al. (2002) Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. Am J Roentgenol 179(1):93–101. https://doi.org/10.2214/ajr.179.1.1790093

    Article  Google Scholar 

  20. Goldberg SN, Saldinger PF, Gazelle GS, et al. (2001) Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intratumoral doxorubicin injection in a rat breast tumor model. Radiology 220(2):420–427. https://doi.org/10.1148/radiology.220.2.r01au44420

    Article  PubMed  CAS  Google Scholar 

  21. Mostafa EM, Ganguli S, Faintuch S, Mertyna P, Goldberg SN (2008) Optimal strategies for combining transcatheter arterial chemoembolization and radiofrequency ablation in rabbit VX2 hepatic tumors. J Vasc Interv Radiol 19(12):1740–1748. https://doi.org/10.1016/j.jvir.2008.08.028

    Article  PubMed  Google Scholar 

  22. Liu Z, Gao F, Yang G, et al. (2014) Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. Tumor Biol 35(8):7407–7413. https://doi.org/10.1007/s13277-014-1976-z

    Article  CAS  Google Scholar 

  23. Brace CL (2010) Microwave tissue ablation: biophysics, technology, and applications. Crit Rev Biomed Eng 38(1):65–78

    Article  PubMed  PubMed Central  Google Scholar 

  24. Brace CL, Laeseke PF, Sampson LA, et al. (2007) Microwave ablation with multiple simultaneously powered small-gauge triaxial antennas: results from an in vivo swine liver model. Radiology 244(1):151–156. https://doi.org/10.1148/radiol.2441052054

    Article  PubMed  Google Scholar 

  25. Xu LF, Sun HL, Chen YT, et al. (2013) Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol 28(3):456–463. https://doi.org/10.1111/jgh.12088

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul Laeseke.

Ethics declarations

Funding

No funding was provided for this study.

Conflict of interest

Christopher L. Brace: (1) consulting fees, NeuWave Medical, Inc., Madison, WI (2) shareholder and consulting fees, Symple Surgical, Inc., Menlo Park, CA. J. Louis Hinshaw: Consulting fees, NeuWave Medical, Inc., Madison, WI. Paul Laeseke: consulting fees, NeuWave Medical, Inc., Madison, WI. Fred T. Lee, Jr: (1) Board Member, Stockholder, and Grant recipient (pending) Histosonics, Inc., Ann Arbor, MI (2) Paid consultant, Ethicon, Inc., Somerville, NJ (3) Stockholder, Elucent, Inc., Minneapolis, MN (4) Patent holder and Royalties, Medtronic/Covidien, Inc., Boulder, CO (5) Stockholder, Zurex, Inc., HealthMyne, Inc., and Eximis Surgical, Inc. Meghan G. Lubner: (1) Grant recipient, Ethicon, Inc., Somerville, NJ (2) Grant recipient, Philips, Amsterdam, Netherlands. Shane A. Wells: consulting fees, NeuWave Medical, Inc., Madison, WI. Timothy J. Ziemlewicz: consulting fees, NeuWave Medical, Inc., Madison, WI.

Ethical approval

All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study prior to undergoing procedures. This retrospective study was approved by our institutional review board, and the requirement for informed consent was waived.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Smolock, A.R., Cristescu, M.M., Hinshaw, A. et al. Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone. Abdom Radiol 43, 2497–2504 (2018). https://doi.org/10.1007/s00261-018-1464-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-018-1464-9

Keywords

Navigation